Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders

Active Cooperative Agreement Awarded Last action

Award ID
UH3DA050316
Recipient
Awarding agency
Obligated
$17,740,946

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date 89% complete
Originally
Place of performance
California, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $1,348,795
Amendment $1,348,795
Amendment $0
Amendment $0
Amendment $5,014,452
Amendment $5,014,452
Original award $5,014,452
Show all 13

Subawards

Subrecipient Amount Awarded
Pharmaron, Inc. Pharmaron has compiled a comprehensive list of recommended studies essential for Sanford Burnham's preclinical candidate nomination and Investigational New Drug… $264,791
Pharmaron, Inc. Pharmaron has compiled a comprehensive list of recommended studies essential for Sanford Burnham's preclinical candidate nomination and Investigational New Drug… $290,290
Pharmaron, Inc. $1,832,660
Regents Of The University Of Minnesota The team at the University of Minnesota will perform work in support of generating lead compound efficacy data. This work may include the studies detailed… $529,980

Quick answers

Who received award UH3DA050316?

UH3DA050316 was awarded to Sanford Burnham Prebys Medical Discovery Institute by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2019.

How much is award UH3DA050316 worth?

$17,740,946 has been obligated on UH3DA050316.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login